Nomura maintains a buy rating on Macrotech Developers with a target price of Rs 1,600, citing strong Q2 performance and anticipated 20% YoY pre-sales growth. For BPCL, Nomura raises the target to Rs 380 despite lower results. Nuvama and Jefferies also maintain buy ratings on Federal Bank (target Rs 235) and Sun Pharma (target Rs 2,150), respectively, highlighting strong performance and growth potential.
| Subscribe To Our Free Newsletter |
